3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
10
Other hematologic neoplasm
7
Genitourinary
5
Plasma cell
4
Breast
4
Tumor-Agnostic
3
Thoracic
3
Myeloid
3
Gynecologic
3
Head & Neck
2
Gastrointestinal
2
Sarcoma
1
Other
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Cisplatin
263
Radiotherapy
166
Cetuximab
159
Docetaxel
105
Fluorouracil
104
pembrolizumab
94
Radiotherapy, Intensity-Modulated
83
Carboplatin
80
Paclitaxel
73
Nivolumab
59
Erlotinib Hydrochloride
35
Surveys and Questionnaires
32
Gemcitabine
32
durvalumab
30
Radiation
29
Drug Therapy
25
Immunohistochemistry
21
Gefitinib
21
Capecitabine
21
tremelimumab
18
Bevacizumab
18
Surgical Procedures, Operative
17
Sorafenib
17
Magnetic Resonance Spectroscopy
17
Ipilimumab
17
Pemetrexed
16
lenvatinib
15
atezolizumab
15
Radiosurgery
15
Gene Expression Profiling
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Diphenhydramine
×
Head & Neck
×
Clear all
NCT03107182
2025-05-06
OPTIMA-II
University of Chicago
Phase 2
Completed
72 enrolled
14 charts
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled